Treatment of the elderly patient with diffuse large B cell lymphoma

British Journal of Haematology

Volumn 157, Issue 2, 2012, Pages 159-170

  Fields, Paul A ^a   Linch, David C ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diffuse large B cell lymphoma; Elderly; Management

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; METHOTREXATE; MITOXANTRONE; PIXANTRONE; PREDNISOLONE; PREDNISONE; RAZOXANE; RITUXIMAB; STEROID; VINCRISTINE; VINDESINE;

AREFLEXIA; AUTONOMIC DYSFUNCTION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CARDIOTOXICITY; CAUSE SPECIFIC SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; CRANIAL NERVE PARALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FRAIL ELDERLY; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; LIFE EXPECTANCY; LUNG EMBOLISM; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; NERVE CONDUCTION; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SCORING SYSTEM; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; WEAKNESS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; VINCRISTINE;

EID: 84859211952     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.09011.x     Document Type: Review

References (94)

1. Aapro, M., Bernard-Marty, C., Brain, E.G., Batist, G., Erdkamp, F., Krzemieniecki, K., Leonard, R., Lluch, A., Monfardini, S., Ryberg, M., Soubeyran, P. & Wedding, U. (2011a) Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Annals of Oncology, 22, 257-267.
2. Aapro, M.S., Bohlius, J., Cameron, D.A., Dal Lago, L., Donnelly, J.P., Kearney, N., Lyman, G.H., Pettengell, R., Tjan-Heijnen, V.C., Walewski, J., Weber, D.C. & Zielinski, C. (2011b) European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer, 47, 8-32.
3. Advani, R.H., Chen, H., Habermann, T.M., Morrison, V.A., Weller, E.A., Fisher, R.I., Peterson, B.A., Gascoyne, R.D., Horning, S.J. & Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group. (2010) Comparison of conventional prognostic indices in patients older than 60years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70years in an elderly prognostic index (E-IPI). British Journal of Haematology, 151, 143-151.
4. Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S. & Noonan, D.M. (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute, 102, 14-25.
5. Arias, E., Rostron, B.L. & Tejada-Vera, B. (2010) United States Life Tables, 2005. National Vital Statistics Reports, 58, 1-132. Hyattsville, MD: National Center for Health Statistics.
6. Bernell, P. & Ohm, L. (1998) Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. British Journal of Haematology, 101, 203-204.
7. Bonnet, C., Fillet, G., Mounier, N., Ganem, G., Molina, T.J., Thiéblemont, C., Fermé, C., Quesnel, B., Martin, C., Gisselbrecht, C., Tilly, H., Reyes, F. & for the Groupe d'Etude des Lymphomes de l'Adulte. (2007) CHOP alone compared with CHOP plus radiotherapy for localised aggressive lymphoma in elderly patients: a study by the Groupe d'etude des Lymphomes de l'adulte. Journal of Clinical Investigation, 25, 787-792.
8. Briggs, J.H. & Miller, T.P. (2000) Combined chemotherapy plus radiotherapy for treatment of early-stage intermediate and high-grade non-Hodgkin's lymphoma. Current Oncology Reports, 2, 176-181.
9. Burton, C., Smith, P., Vaughan-Hudson, G., Qian, W., Hoskin, P., Cunningham, D., Hancock, B. & Linch, D. (2005) Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. British Journal of Haematology, 130, 536-541.
10. Burton, C., Linch, D., Hoskin, P., Milligan, D., Dyer, M.J., Hancock, B., Mouncey, P., Smith, P., Qian, W., MacLennan, K., Jack, A., Webb, A. & Cunningham, D. (2006) A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. British Journal of Cancer, 94, 806-813.
11. Chambers, S.M., Shaw, C.A., Gatza, C., Fisk, C.J., Donehower, L.A. & Goodell, M.A. (2007) Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biology, 5, e201.
12. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases, 40, 373-383.
13. Chau, I., Harries, M., Cunningham, D., Hill, M., Ross, P.J., Archer, C.D., Norman, A.R., Wotherspoon, A., Koh, D.M., Gill, K., Uzzell, M., Prior, Y. & Catovsky, D. (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. British Journal of Haematology, 120, 970-977.
14. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
15. Corazzelli, G., Frigeri, F., Arcamone, M., Lucania, A., Rosariavilla, M., Morelli, E., Amore, A., Capobianco, G., Caronna, A., Becchimanzi, C., Volzone, F., Marcacci, G., Russo, F., De Filippi, R., Mastrullo, L. & Pinto, A. (2011) Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy. British Journal of Haematology, 154, 579-589.
16. Cunningham, D., Smith, P., Mouncey, P., Qian, W., Jack, A., Pocock, C., Ardeshna, K.M., Radford, J.A., Davies, A.J., McMillan, A. & Linch, D.C. (2011) RCHOP14 vs RCHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnoses diffuse large B-cell non-Hodgkin lymphoma. Journal of Clinical Oncology, 29 (Suppl.), Abstract 8000.
17. van Dalen, E.C., Caron, H.N., Dickinson, H.O. & Kremer, L.C. (2008) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database System Review, 2, CD003917.
18. Doorduijn, J.K., van der Holt, B., van Imhoff, G.W., van der Hem, K.G., Kramer, M.H., van Oers, M.H., Ossenkoppele, G.J., Schaafsma, M.R., Verdonck, L.F., Verhoef, G.E., Steijaert, M.M., Buijt, I., Uyl-de Groot, C.A., van Agthoven, M., Mulder, A.H. & Sonneveld, P. (2003) CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 21, 3041-3050.
19. Ershler, W.B., Sheng, S., McKelvey, J., Artz, A.S., Denduluri, N., Tecson, J., Taub, D.D., Brant, L.J., Ferrucci, L. & Longo, D.L. (2005) Serum erythropoietin and aging: a longitudinal analysis. Journal of the American Geriatrics Society, 53, 1360-1365.
20. Extermann, M. & Hurria, A. (2007) Comprehensive geriatric assessment for older patients with cancer. Journal of Clinical Oncology, 25, 1824-1831.
21. Ferreri, A.J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G.A., Frezzato, M., Cabras, M.G., Fabbri, A., Corazzelli, G., Ilariucci, F., Rossi, G., Soffietti, R., Stelitano, C., Vallisa, D., Zaja, F., Zoppegno, L., Aondio, G.M., Avvisati, G., Balzarotti, M., Brandes, A.A., Fajardo, J., Gomez, H., Guarini, A., Pinotti, G., Rigacci, L., Uhlmann, C., Picozzi, P., Vezzulli, P., Ponzoni, M., Zucca, E., Caligaris-Cappio, F. & Cavalli, F. (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, 374, 1512-1520.
22. Feugier, P., Virion, J.M., Tilly, H., Haioun, C., Marit, G., Macro, M., Bordessoule, D., Recher, C., Blanc, M., Molina, T., Lederlin, P. & Coiffier, B. (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large B-cell lymphomas: influence of rituximab. Annals of Oncology, 15, 129-133.
23. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with Diffuse Large B-cell Lymphoma: a study by the Groupe d'Etude des Lymphomes d'Adulte. Journal of Clinical Oncology, 23, 4117-4126.
24. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A. & Miller, Jr, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002-1006.
25. Fosså, A., Santoro, A., Hiddemann, W., Truemper, L., Niederle, N., Buksmaui, S., Bonadonna, G., Seeber, S. & Nowrousian, M.R. (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 17, 3786-3792.
26. Glantz, M.J., LaFollette, S., Jaeckle, K.A., Shapiro, W., Swinnen, L., Rozental, J.R., Phuphanich, S., Rogers, L.R., Gutheil, J.C., Batchelor, T., Lyter, D., Chamberlain, M., Maria, B.L., Schiffer, C., Bashir, R., Thomas, D., Cowens, W. & Howell, S.B. (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. Journal of Clinical Oncology, 17, 3110-3116.
27. Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. & Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 3121-3127.
28. Hainsworth, J.D., Flinn, I.W., Spigel, D.R., Clark, B.L., Griner, P.L., Vazquez, E.R., Doss, H.H., Shipley, D., Franco, L.A., Burris, 3rd, H.A., Greco, F.A. & Sarah Cannon Oncology Research Consortium. (2010) Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clinical Lymphoma, Myeloma & Leukemia, 10, 44-50.
29. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Müller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immuno-histochemistry using a tissue microarray. Blood, 103, 275-282.
30. He, J., Ogden, L.G., Bazzano, L.A., Vupputuri, S., Loria, C. & Whelton, P.K. (2001) Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Archives of Internal Medicine, 161, 996-1002.
31. Hershman, D.L., McBride, R.B., Eisenberger, A., Tsai, W.Y., Grann, V.R. & Jacobson, J.S. (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 3159-3165.
32. Hurria, A., Gupta, S., Zauderer, M., Zuckerman, E.L., Cohen, H.J., Muss, H., Rodin, M., Panageas, K.S., Holland, J.C., Saltz, L., Kris, M.G., Noy, A., Gomez, J., Jakubowski, A., Hudis, C. & Kornblith, A.B. (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer, 104, 1998-2005.
33. Janssen-Heijnen, M.L., van Spronsen, D.J., Lemmens, V.E., Houterman, S., Verheij, K.D. & Coebergh, J.W.W. (2005) A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. British Journal of Haematology, 129, 597-606.
34. Johnston, K.M., Marra, C.A., Connors, J.M., Najafzadeh, M., Sehn, L. & Peacock, S.J. (2010) Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health, 13, 703-711.
35. Katz, S., Ford, A.B., Moscowitz, R.W., Jackson, B.A. & Jaffe, M.W. (1963) Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA, 185, 914-919.
36. Kim, B.J., Park, H.R., Roh, H.J., Jeong, D.S., Kim, B.S., Park, K.W., Cho, S.C., So, Y.T., Oh, S.Y. & Kim, S.J. (2010) Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Quality of Life Research, 19, 1097-1103.
37. Kuderer, N.M., Dale, D.C., Crawford, J. & Lyman, G.H. (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Journal of Clinical Oncology, 25, 3158-3167.
38. Lawton, M.P. & Brody, E.M. (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist, 9, 179-186.
39. Linch, D.C., Vaughan Hudson, B., Hancock, B.W., Hoskin, P.J., Cunningham, D.C., Newland, A.C., Milligan, D.W., Stevenson, P.A., Wood, J.K., MacLennan, K.A., Anderson, L., Gregory, W.M. & Vaughan Hudson, G. (1996) A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. British Journal of Cancer, 74, 318-322.
40. Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., Linch, D., Robinson, M., Jack, A. & Hoskin, P. (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiotherapy and Oncology, 100, 86-92.
41. Luminari, S., Montanini, A., Caballero, D., Bologna, S., Notter, M., Dyer, M.J., Chiappella, A., Briones, J., Petrini, M., Barbato, A., Kayitalire, L. & Federico, M. (2010) Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Annals of Oncology, 21, 1492-1499.
42. Lyman, G.H. & Delgado, D.J. (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer, 98, 2402-2409.
43. Lyman, G.H., Lyman, C.G., Sanderson, R.A. & Balducci, L. (1993) Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. Journal of the National Cancer Institute, 85, 488-493.
44. Lyman, G.H., Kuderer, N.M. & Balducci, L. (1998) Cancer care in the elderly: cost and quality-of-life considerations. Cancer Control, 5, 347-354.
45. Maartense, E., Kluin-Nelemans, H.C., le Cessie, S., Kluin, P.M., Snijder, S. & Noordijk, E.M. (2000) Different age limits for elderly patients with indolent and aggressive non-hodgkin lymphoma and the role of relative survival with increasing age. Cancer, 89, 2667-2676.
46. Macmillan, A. (2005) Central nervous system-directed preventative therapy in adults with lymphoma. British Journal of Haematology, 131, 13-21.
47. Maione, P., Perrone, F., Gallo, C., Manzione, L., Piantedosi, F., Barbera, S., Cigolari, S., Rosetti, F., Piazza, E., Robbiati, S.F., Bertetto, O., Novello, S., Migliorino, M.R., Favaretto, A., Spatafora, M., Ferrau, F., Frontini, L., Bearz, A., Repetto, L., Gridelli, C., Barletta, E., Barzelloni, M.L., Iaffaioli, R.V., De Maio, E., Di Maio, M., De Feo, G., Sigoriello, G., Chiodini, P., Cioffi, A., Guardasole, V., Angelini, V., Rossi, A., Bilancia, D., Germano, D., Lamberti, A., Pontillo, V., Brancaccio, L., Renda, F., Romano, F., Esani, G., Gambaro, A., Vinante, O., Azzarello, G., Clerici, M., Bollina, R., Belloni, P., Sannicolo, M., Ciuffreda, L., Parello, G., Cabiddu, M., Sacco, C., Sibau, A., Porcile, G., Castiglione, F., Ostellino, O., Monfardini, S., Stefani, M., Scagliotti, G. & Selvaggi, G. De Marinis, F., Martelli, O., Gasparini, G., Morabito, A., Gattuso, D., Colucci, G., Galetta, D., Giotta, F., Gebbia, V., Borsellino, N., Testa, A., Malaponte, E., Capuano, M.A., Angiolillo, M., Sollitto, F., Tirelli, U., Spazzapan, S., Adamo, V., Altavilla, G., Scimone, A., Hopps, M.R., Tartamella, F., Ianniello, G.P., Tinessa, V., Failla, G., Bordonaro, R., Gebbia, N., Valerio, M.R., D'Aprile, M., Veltri, E., Tonato, M., Darwish, S., Romito, S., Carrozza, F., Barni, S., Ardizzoia, A., Corradini, G.M., Pavia, G., Belli, M., Colantuoni, G., Galligioni, E., Caffo, O., Labianca, R., Quadri, A., Cortesi, E., D'Auria, G., Fava, S., Calcagno, A., Luporini, G., Locatelli, M.C., Di Costanzo, F., Gasperoni, S., Isa, L., Candido, P., Gaion, F., Palazzolo, G., Nettis, G., Annamaria, A., Rinaldi, M., Lopez, M., Felletti, R., Di Negro, G.B., Rossi, N., Calandriello, A., Maiorino, L., Mattioli, R., Celano, A., Schiavon, S., Illiano, A., Raucci, C.A., Caruso, M., Foa, P., Tonini, G., Curcio, C. & Cazzaniga, M. (2005) Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. Journal of Clinical Oncology, 23, 6865-6872.
48. Marchesini, G., Bua, V., Brunori, A., Bianchi, G., Pisi, P., Fabbri, A., Zoli, M. & Pisi, E. (1988) Galactose elimination capacity and liver volume in aging man. Hepatology, 8, 1079-1083.
49. Mareschal, S., Lanic, H., Ruminy, P., Bastard, C., Tilly, H. & Jardin, F. (2011) The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica, 96, 1888-1890.
50. Marley, S.B., Lewis, J.L., Davidson, R.J., Roberts, I.A., Dokal, I., Goldman, J.M. & Gordon, M.Y. (1999) Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children. British Journal of Haematology, 106, 162-166.
51. Merli, F., Luminari, S., Rossi, G., Mammi, C., Marcheselli, L., Alvarez, I., Tucci, A., Stelitano, C., Ilariucci, F., Musso, M., Baldini, L., Fragasso, A., Chiappella, A. & Frederico, M. (2010) Outcome of elderly frail patients with diffuse large B-cell lymphoma (DLBCL) prospectively identified by comprehensive geriatric assessment (CGA). Results from a study of the Intergruppo Italiano Linfomi (IIL). Blood (ASH Annual Meeting Abstracts), 116, Abstract 1771.
52. Miller, T.A. (1991) A Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). University of Pittsburg, Pittsburg, PA.
53. Miller, T.P., Leblanc, M., Chase, E. & Fisher, R.I. (2001) Chemotherapy alone compared with chemotherapy plus radiotherapy for early stage aggressive non-Hodgkin's lymphoma: update of the Southwest Oncology Group randomised trial. Annals of Hematology, 80 (Suppl. 3), B154, Abstract 52.
54. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56, 185-229.
55. Moccia, A.A., Schaff, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Gascoyne, R., Connors, J.M. & Sehn, L.H. (2009) R-CHOP with etoposide substituted for doxorubicin (R-CEOP); excellent outcome in diffuse large B-cell lymphoma for patients with a contraindication to anthracyclines. Blood (ASH Annual Meeting Abstracts, 114, Abstract 408.
56. van Moorsel, C.J., Veerman, G., Ruiz van Haperen, V.W., Bergman, A.M., Jensen, P.B., Sehested, M. & Peters, G.J. (1998) Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines. Advances in Experimental Medicine and Biology, 431, 661-665.
57. Mora, O. & Zucca, E. (2007) Management of elderly patients with hematological neoplasms. Annals of Oncology, 18 (Suppl. 1), i49-i53. Review.
58. Mukherji, D. & Pettengell, R. (2010) Pixantrone fot the treatment of aggressive non-Hodgkin's lymphoma. Expert Opinion on Pharmacotherapy, 11, 1915-1923.
59. Osby, E., Hagberg, H., Kvaloy, S., Teerenhovi, L., Anderson, H., Cavallin-Stahl, E., Holte, H., Myhre, J., Pertovaara, H. & Bjorkholm, M. (2003) CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood, 101, 3840-3848.
60. Oyama, T., Yamamoto, K., Asano, N., Oshiro, A., Suzuki, R., Kagami, Y., Morishima, Y., Takeuchi, K., Izumo, T., Mori, S., Ohshima, K., Suzumiya, J., Nakamura, N., Abe, M., Ichimura, K., Sato, Y., Yoshino, T., Naoe, T., Shimoyama, Y., Kamiya, Y., Kinoshita, T. & Nakamura, S. (2007) Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clinical Cancer Research, 13, 5124-5132.
61. Pal, S.K. & Hurria, A. (2010) Impact of age, sex, and comorbidity on cancer therapy and disease progression. Journal of Clinical Oncology, 10, 4086-4093.
62. Persky, D.O., Unger, J.M., Spier, C.M., Stea, B., LeBlanc, M., McCarty, M.J., Rimsza, L.M., Fisher, R.I., Miller, T.P. & Southwest Oncology Group. (2008) Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. Journal of Clinical Oncology, 10, 2258-2263.
63. Pettengell, R., Schwenkglenks, M., Leonard, R., Bosly, A., Paridaens, R., Constenla, M., Szucs, T.D. & Jackisch, C. (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer, 16, 1299-1309.
64. Peyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J.F., Castaigne, S., Coiffier, B., Haioun, C., Bologna, S., Fitoussi, O., Lepeu, G., Fruchart, C., Bordessoule, D., Blanc, M., Delarue, R., Janvier, M., Salles, B., André, M., Fournier, M., Gaulard, P., Tilly, H. & Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 12, 460-468.
65. Pfreundschuh, M., Trümper, L., Kloess, M., Schmits, R., Feller, A.C., Rübe, C., Rudolph, C., Reiser, M., Hossfeld, D.K., Eimermacher, H., Hasenclever, D., Schmitz, N., Loeffler, M. & German High-Grade Non-Hodgkin's Lymphoma Study Group. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104, 634-641.
66. Pfreundschuh, M., Schubert, J. & Ziepert, M. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9, 105-116.
67. Piccirillo, J.F., Tierney, R.M., Costas, I., Grove, L. & Spitznagel, Jr, E.L. (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA, 291, 2441-2447.
68. Recher, C., Coiffier, B., Haioun, C., Ferme, C., Molina, T.J., Casanovas, O., Gisslbrecht, C., Bosly, A., Laurent, G., Morschhauser, F., Ghesquieres, H., Jardin, F., Bologna, S., Fruchart, C., Canioni, D., corront, B., Gabarre, G., Bonnet, C., Janvier, M. & Tilly, H. (2010) A prospective randomised study comparing dose intensive immuno-chemotherapy with R-ACVBP vs standard R_CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL): GELA study LNH03-2B. Blood (ASH Annual Meeting Abstracts)116, No 21, Abstract 109.
69. Savage, D.G., Rule, S.A., Tighe, M., Garrett, T.J., Oster, M.W., Lee, R.T., Ruiz, J., Heitjan, D., Keohan, M.L., Flamm, M. & Johnson, S.A. (2000) Gemcitabine for relapsed or resistant lymphoma. Annals of Oncology, 11, 595-597.
70. Sawyer, D.B., Peng, X., Chen, B., Pentassuglia, L. & Lim, C.C. (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Progress in Cardiovascular Diseases, 53, 105-113.
71. van de Schans, S.A., Gondos, A., van Spronsen, D.J., Rachtan, J., Holleczek, B., Zanetti, R., Coebergh, J.W., Janssen-Heijnen, M.L. & Brenner, H. (2011) Improving relative survival, but large remaining differences in survival for non-Hodgkin's lymphoma across Europe and the United States from 1990 to 2004. Journal of Clinical Oncology, 10, 192-199.
72. Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Sutherland, J., Gascoyne, R.D. & Connors, J.M. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome that the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 1857-1861.
73. Shin, H.W., Kim, H., Son, J., Yoon, H.J., Park, H.S., Cho, Y.K., Han, C.D., Nam, C.W., Hur, S.H., Kim, Y.N. & Kim, K.B. (2010) Tissue Doppler imaging as a prognostic marker for cardiovascular events in heart failure with preserved ejection fraction and atrial fibrillation. Journal of the American Society of Echocardiography, 23, 755-761.
74. Sioka, C. & Kyritsis, A.P. (2009) Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemotherapy and Pharmacology, 63, 761-767.
75. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., Bennett, C.L., Cantor, S.B., Crawford, J., Cross, S.J., Demetri, G., Desch, C.E., Pizzo, P.A., Schiffer, C.A., Schwartzberg, L., Somerfield, M.R., Somlo, G., Wade, J.C., Wade, J.L., Winn, R.J., Wozniak, A.J. & Wolff, A.C. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology, 24, 3187-3205.
76. Smith, L.A., Cornelius, V.R., Plummer, C.J., Levitt, G., Verrill, M., Canney, P. & Jones, A. (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 29, 337.
77. Sonneveld, P., van Putten, W., Biesma, D., Holte, H., van Marwijk Kooij, M., Kramer, M.H., Wijermans, P.W., Steijaert, M., van Imhoff, G.W., Lugtenburg, P.J., Huijgens, P.C. & Eriksson, M. (2006) Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell non-Hodgkin's lymphoma in elderly patients. Blood (ASH Annual Meeting Abstracts, 108, Abstract 210.
78. Swain, S.M. & Vici, P. (2004) The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatemnt; expert review panel. Journal of Cancer Research and Clinical Oncology, 130, 1-7.
79. The International non-Hodgkin's Lymphoma Prognostic Factors Project. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's lymphoma prognostic factors project. New England Journal of Medicine, 329, 987-994.
80. Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., Attal, M., Fillet, G., Guettier, C., Molina, T.J., Gisselbrecht, C. & Reyes, F. (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, 4284-4289.
81. Tirelli, U., Fratino, L., Balzarotti, M., Uziel, L., Giacalone, A., Ferreri, A., Santoro, A. & Spina, M. (2011) Comprehensive geriatric assessment-adapted chemotherapy in elderly patients (<70years) with diffuse large B-cell lymphoma (DLBCL): final results and long-term follow-up. Annals of Oncology, 22 (Suppl. 4), Abstract 105.
82. Trumper, L., Kloess, M., Schmits, R., Kaiser, U., Engert, A., Reiser, M., Hoffkes, H., Kroschinsky, F., Mesters, R., Feller, A.C., Loffler, M., Pfreundschuh, M. & for the German High-Grade non-Hodgkin's Lymphoma Study Group (DSHNHL). (2002) Significant dose escalation of idarubicin in the treatment of aggressive non-Hodgkin's lymphoma leads to increased hematoxicity without improvement of efficacy: final results of a phase I/II trial of the German high grade NHL Study Group (DSHNHL). Annals of Oncology, 13 (Suppl. 2), 548.
83. Tsavaris, N., Kosmas, C., Vadiaka, M., Giannouli, S., Siakantaris, M.P., Vassilakopoulos, T. & Pangalis, G.A. (2002) Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Research, 22, 1845-1848.
84. Vanasse, G.J. & Berliner, N. (2010) Anemia in elderly patients: an emerging problem for the 21st century. Hematology American Society of Hematology Education Program, 2010, 271-275.
85. Vaughan Hudson, B., Vaughan Hudson, G., MacLennan, K.A., Anderson, L. & Linch, D.C. (1994) Clinical Stage I non-Hodgkin's lymphoma: a long term follow up of patients treated with radiotherapy alone as initial therapy. British Journal of Cancer, 69, 1088-1093.
86. Verstappen, C.C., Koeppen, S., Heimans, J.J., Huijgens, P.C., Scheulen, M.E., Strumberg, D., Kiburg, B. & Postma, T.J. (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology, 64, 1076-1077.
87. Villa, D., Connors, J.M., Shenkier, T.N., Gascoyne, R.D., Sehn, L.H. & Savage, K.J. (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Annals of Oncology, 21, 1046-32.
88. Visani, G. & Isidori, A. (2009) Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. Expert Review of Anticancer Therapy, 9, 357-363.
89. Von Hoff, D.D., Layard, M.W., Basa, P., Davis, Jr, H.L., Von Hoff, A.L., Rozencweig, M. & Muggia, F.M. (1979) Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 91, 710-717.
90. Wynne, H.A., Cope, L.H., Mutch, E., Rawlins, M.D., Woodhouse, K.W. & James, O.F. (1989) The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology, 9, 297-301.
91. Yancik, R. & Ries, L.A. (2004) Cancer in older persons: an international issue in an aging world. Seminars in Oncology, 31, 128-136.
92. Ziepert, M., Schmits, R., Trümper, L., Pfreundschuh, M. & Loeffler, M. & German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). (2008) Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. Annals of Oncology, 19, 752-762.
93. Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M. & Loeffler, M. (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. Journal of clinical oncology, 28, 2373-2383.
94. Zinzani, P.L., Martelli, M., Storti, S., Musso, M., Cantonetti, M., Leone, G., Cajozzo, A., Papa, G., Iannitto, E. & Perrotti, A. (1995) Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate grade non-Hodgkin's lymphoma. Leukaemia Lymphoma, 19, 329-333.